SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
Conditions: Type 2 Diabetes; Type 1 Diabetes Interventions: Drug: Empagliflozin 25 MG; Other: Placebo Sponsors: The University of Texas Health Science Center at San Antonio; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Endocrinology | Research | Science | SGLT2 Inhibitors | Texas University | Urology & Nephrology